Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Double-Blind, Single Dose, One-Day Early Administration, Multicentre Study Comparing the Efficacy and Safety of Acyclovir Lauriad 50 mg Muco-Adhesive Buccal Tablet to Matching Placebo, in the Treatment of Herpes Labialis in Immunocompetent Patients

Next Previous
X
Search
Trial Profile

A Randomised, Double-Blind, Single Dose, One-Day Early Administration, Multicentre Study Comparing the Efficacy and Safety of Acyclovir Lauriad 50 mg Muco-Adhesive Buccal Tablet to Matching Placebo, in the Treatment of Herpes Labialis in Immunocompetent Patients

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aciclovir (Primary)
  • Indications Herpes labialis
  • Focus Registrational; Therapeutic Use
  • Acronyms LIP
  • Sponsors Valerio Therapeutics

    • Most Recent Events

    • 24 Feb 2016 According to a Cipher Pharmaceuticals media release, Sitavig was accepted for review by Health Canada.
    • 03 Jul 2012 Planned number of patients changed from 1900 to 1950 as reported by European Clinical Trials Database.
    • 14 Dec 2009 Secondary endpoint 'Clinical response rate' has been met.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top